Alpaca single B cell interrogation and heavy-chain-only antibody discovery on an optofluidic platform.

Q2 Medicine Antibody Therapeutics Pub Date : 2023-07-01 DOI:10.1093/abt/tbad018
Mariya B Shapiro, Jacqueline Boucher, Anna Brousseau, Amin Dehkharghani, Justin Gabriel, Vishal Kamat, Ketan Patil, Feng Gao, Jennifer Walker, Ryan Kelly, Colby A Souders
{"title":"Alpaca single B cell interrogation and heavy-chain-only antibody discovery on an optofluidic platform.","authors":"Mariya B Shapiro,&nbsp;Jacqueline Boucher,&nbsp;Anna Brousseau,&nbsp;Amin Dehkharghani,&nbsp;Justin Gabriel,&nbsp;Vishal Kamat,&nbsp;Ketan Patil,&nbsp;Feng Gao,&nbsp;Jennifer Walker,&nbsp;Ryan Kelly,&nbsp;Colby A Souders","doi":"10.1093/abt/tbad018","DOIUrl":null,"url":null,"abstract":"<p><p><i>In vivo</i> VHH discovery approaches have been limited by the lack of methodologies for camelid B cell interrogation. Here, we report a novel application of the Beacon® optofluidic platform to the discovery of heavy-chain-only antibodies by screening alpaca B cells. Methods for alpaca B cell enrichment, culture, IgG2/3 detection, and sequencing were developed and used to discover target-specific VHH from an alpaca immunized with prostate-specific membrane antigen (PSMA) or a second target. PSMA-specific hits were expressed as VHH-Fc and characterized using label-free techniques. Anti-PSMA IgG2/3 titer plateaued on day 153, when on-Beacon IgG2/3 secretion and target binding rates peaked. Of 13 recombinantly expressed VHH-Fc, all but one bound with nanomolar affinity, and five were successfully humanized. Repertoire sequencing uncovered additional variants within the clonal lineages of the validated hits. The establishment of this workflow extends the powerful Beacon technology to enable rapid VHH discovery directly from natural camelid immune repertoires.</p>","PeriodicalId":36655,"journal":{"name":"Antibody Therapeutics","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/7f/ef/tbad018.PMC10481890.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Antibody Therapeutics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/abt/tbad018","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

In vivo VHH discovery approaches have been limited by the lack of methodologies for camelid B cell interrogation. Here, we report a novel application of the Beacon® optofluidic platform to the discovery of heavy-chain-only antibodies by screening alpaca B cells. Methods for alpaca B cell enrichment, culture, IgG2/3 detection, and sequencing were developed and used to discover target-specific VHH from an alpaca immunized with prostate-specific membrane antigen (PSMA) or a second target. PSMA-specific hits were expressed as VHH-Fc and characterized using label-free techniques. Anti-PSMA IgG2/3 titer plateaued on day 153, when on-Beacon IgG2/3 secretion and target binding rates peaked. Of 13 recombinantly expressed VHH-Fc, all but one bound with nanomolar affinity, and five were successfully humanized. Repertoire sequencing uncovered additional variants within the clonal lineages of the validated hits. The establishment of this workflow extends the powerful Beacon technology to enable rapid VHH discovery directly from natural camelid immune repertoires.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
羊驼单B细胞探询及光流平台上仅重链抗体的发现。
由于缺乏对骆驼B细胞的研究方法,体内VHH发现方法受到了限制。在这里,我们报告了Beacon®光流体平台在筛选羊驼B细胞中发现仅重链抗体的新应用。建立了羊驼B细胞富集、培养、IgG2/3检测和测序的方法,并用于从前列腺特异性膜抗原(PSMA)或第二靶标免疫的羊驼中发现靶标特异性VHH。psma特异性命中表达为VHH-Fc,并使用无标记技术进行表征。抗psma IgG2/3滴度在第153天趋于稳定,此时on- beacon IgG2/3分泌和靶结合率达到峰值。在13个重组表达的VHH-Fc中,除1个外,其余均具有纳米级亲和力,其中5个成功人源化。保留序列测序在验证命中的克隆谱系中发现了额外的变体。该工作流程的建立扩展了强大的Beacon技术,可以直接从天然骆驼免疫库中快速发现VHH。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Antibody Therapeutics
Antibody Therapeutics Medicine-Immunology and Allergy
CiteScore
8.70
自引率
0.00%
发文量
30
审稿时长
8 weeks
期刊最新文献
AI-based antibody discovery platform identifies novel, diverse, and pharmacologically active therapeutic antibodies against multiple SARS-CoV-2 strains. FcRider: a recombinant Fc nanoparticle with endogenous adjuvant activities for hybrid immunization. A pan-allelic human SIRPα-blocking antibody, ES004-B5, promotes tumor killing by enhancing macrophage phagocytosis and subsequently inducing an effective T-cell response. Correction to: A case study of a bispecific antibody manufacturability assessment and optimization during discovery stage and its implications. The process using a synthetic library that generates multiple diverse human single domain antibodies.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1